PD-1/PD-L1 checkpoint blockadeReduction in tumor burden.Adoptive iNKT cell therapy and IL-6Ra+ NK cell ablationReduction in obesity, hyperlipidemia and leptin production, and upregulation of anti-inflammatory cytokines. Potential improved treatment response when combining checkpoint blockade with adoptive NK cell therapy. The gene discussed is LEP; the disease is obesity due to melanocortin 4 receptor deficiency.